<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="114148"><DrugName>mRNA-3927</DrugName><DrugSynonyms><Name><Value>mRNA-3927</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PCCA + PCCB gene therapy (lipid nanoparticles, propionic acidemia), ModeRNA Therapeutics</Value></Name></DrugSynonyms><CompanyOriginator id="1060964">ModeRNA Therapeutics</CompanyOriginator><CompaniesPrimary><Company id="1060964">ModeRNA Therapeutics</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1060964" type="Company"><TargetEntity id="5035560401" type="organizationId">Modernatx Inc</TargetEntity></SourceEntity><SourceEntity id="1825" type="ciIndication"><TargetEntity id="E71.121" type="ICD10"/><TargetEntity id="D056693" type="MeSH"/><TargetEntity id="35" type="ORPHANET"/><TargetEntity id="-1905138095" type="omicsDisease"/><TargetEntity id="2685" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="DR">Discovery</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1825">Propionic acidemia</Indication></IndicationsPrimary><ActionsPrimary><Action id="173660">PCCA gene stimulator</Action></ActionsPrimary><ActionsSecondary><Action id="4789">Lipid based gene therapy</Action></ActionsSecondary><Technologies><Technology id="103">Oligonucleotide</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="740">Infusion</Technology><Technology id="599">Nanoparticle formulation injectable</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><LastModificationDate>2019-06-18T10:14:20.000Z</LastModificationDate><ChangeDateLast>2019-01-08T00:00:00.000Z</ChangeDateLast><AddedDate>2019-01-08T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1060964" linkType="Company"&gt;ModeRNA Therapeutics&lt;/ulink&gt; is investigating mRNA-3927, a mRNA-based therapeutic agent encoding human propionyl-CoA carboxylase alpha and beta subunits (PCCA and PCCB) that directs the liver expression of the encoded genes, encapsulated into lipid nanoparticles, for the potential treatment of type I and II propionic acidemia (PA) [&lt;ulink linkID="1996086" linkType="Reference"&gt;1996086&lt;/ulink&gt;], [&lt;ulink linkID="2053237" linkType="Reference"&gt;2053237&lt;/ulink&gt;], [&lt;ulink linkID="2107941" linkType="Reference"&gt;2107941&lt;/ulink&gt;], [&lt;ulink linkID="2107960" linkType="Reference"&gt;2107960&lt;/ulink&gt;], [&lt;ulink linkID="2135892" linkType="Reference"&gt;2135892&lt;/ulink&gt;]. In January 2018, mRNA-3927 was reported to be in preclinical development [&lt;ulink linkID="1996086" linkType="Reference"&gt;1996086&lt;/ulink&gt;]; in January 2019, this was still the case [&lt;ulink linkID="2107960" linkType="Reference"&gt;2107960&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In December 2018, the FDA granted Orphan Drug Designation to messenger ribonucleic acid-based therapeutic agent encoding human propionyl-CoA carboxylase alpha and beta subunits, presumed to be mRNA-3927, for the treatment of  propionic acidemia [&lt;ulink linkID="2107941" linkType="Reference"&gt;2107941&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In March 2019, the COMP recommended granting Orphan designation to modified mRNA encoding human propionyl-coenzyme A carboxylase alpha and beta subunits encapsulated into lipid nanoparticles for treatment of propionic acidemia [&lt;ulink linkID="2135892" linkType="Reference"&gt;2135892&lt;/ulink&gt;]; in April 2019, the Orphan designation was granted [&lt;ulink linkID="2151157" linkType="Reference"&gt;2151157&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In January 2018, mRNA-3927 was reported to be in preclinical development [&lt;ulink linkID="1996086" linkType="Reference"&gt;1996086&lt;/ulink&gt;]; in July 2018, preclinical development was ongoing [&lt;ulink linkID="2053237" linkType="Reference"&gt;2053237&lt;/ulink&gt;]. In January 2019, the program was listed in preclinical development [&lt;ulink linkID="2107960" linkType="Reference"&gt;2107960&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1060964">ModeRNA Therapeutics</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1825">Propionic acidemia</Indication><StatusDate>2019-03-19T00:00:00.000Z</StatusDate><Source id="2135892" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1060964">ModeRNA Therapeutics</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1825">Propionic acidemia</Indication><StatusDate>2018-01-08T00:00:00.000Z</StatusDate><Source id="1996086" type="PR"/></DevelopmentStatusCurrent></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1060964">ModeRNA Therapeutics</OwnerCompany><Country id="EU">EU</Country><Indication id="1825">Propionic acidemia</Indication><AwardedIndication>Treatment of propionic acidaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2019-04-24T00:00:00.000Z</MileStoneDate><Source id="2151157" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1060964">ModeRNA Therapeutics</OwnerCompany><Country id="EU">EU</Country><Indication id="1825">Propionic acidemia</Indication><AwardedIndication>Treatment of propionic acidaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2019-03-21T00:00:00.000Z</MileStoneDate><Source id="2135892" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1060964">ModeRNA Therapeutics</OwnerCompany><Country id="US">US</Country><Indication id="1825">Propionic acidemia</Indication><AwardedIndication>Treatment of propionic acidemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-12-05T00:00:00.000Z</MileStoneDate><Source id="2107941" type="CORPORATE"/></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2151157" linkType="reference" linkID="2151157"&gt;2151157&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="4363226" number="WO-2019018765" title="Modified mRNA encoding a propionyl-Coa carboxylase and uses thereof"/><PatentFamily id="4525751" number="WO-2019104195" title="Polynucleotides encoding propionyl-CoA carboxylase alpha and beta subunits for the treatment of propionic acidemia"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="ModeRNA Therapeutics" id="1060964"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>